In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?

<iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Biotech ETF (BBH) are both healthcare-focused exchange-traded funds that cater to different aspects of the industry. IHE concentrates on well-established pharmaceutical companies, while BBH focuses on high-growth biotechnology firms. Both ETFs allow investors to gain concentrated exposure to specific sub-sectors of the healthcare market, enabling them to potentially outperform general market indices through targeted thematic investments.

BBH's strategy involves targeting the biotechnology industry using a concentrated index composed of 24 stocks. In contrast, IHE casts a wider net, encompassing the entire established U.S. pharmaceutical landscape. Investors have the option to choose between these two funds based on their desired risk-reward profile within the drug development and medical innovation sectors.

Their choice will depend on whether they anticipate strong growth in genetics-related industries or prefer the stability offered by pharmaceutical giants with diversified cash flows.

The beta of an ETF measures its price volatility relative to the S&P 500. The beta value is calculated based on monthly returns over the fund's available history, which can extend up to five years. In terms of short-term performance, the 1-year return represents the total return generated by the fund over the trailing 12-month period. Lastly, the dividend yield is calculated as the trailing-12-month distribution yield as of the close of trading on August 13, 2026.